Strength Training Response of Muscle in GLP-1 Users
Virginia Polytechnic Institute and State University
Summary
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Eligibility
- Age range
- 50+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Age, 50y+ * Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less * Weight \<300 lb * Pass a health and exercise readiness screening Exclusion Criteria: * Age \<50 * Weight \>300 lb * Osteoporosis * Active metabolic, neoplastic, or cardiovascular disease * Unable or unwilling to provide consent
Interventions
- BehavioralStrength Training
Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
- OtherWait first, then strength training
Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
Location
- Virginia TechBlacksburg, Virginia